NIDDM
MCID: DBT026
MIFTS: 92

Diabetes Mellitus, Noninsulin-Dependent (NIDDM)

Categories: Endocrine diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Diabetes Mellitus, Noninsulin-Dependent

MalaCards integrated aliases for Diabetes Mellitus, Noninsulin-Dependent:

Name: Diabetes Mellitus, Noninsulin-Dependent 58 13 39 41
Insulin Resistance 58 30 56 6 17 74
Type 2 Diabetes Mellitus 39 12 26 38 15
Niddm 58 12 26 76 56
Diabetes Mellitus, Non-Insulin-Dependent 58 26 76 74
Noninsulin-Dependent Diabetes Mellitus 58 26 76
Insulin Resistance, Severe, Digenic 58 13 6
Diabetes Mellitus, Type 2 58 26 45
Diabetes Mellitus Type 2 76 30 6
Maturity-Onset Diabetes 58 26 76
T2d 58 26 76
Hypertension, Insulin Resistance-Related, Susceptibility to 58 6
Diabetes Mellitus, Noninsulin-Dependent, Association with 58 6
Diabetes Mellitus, Type 2, Susceptibility to 58 6
Insulin Resistance, Susceptibility to 58 6
Adult-Onset Diabetes Mellitus 26 76
Diabetes Mellitus, Type Ii 58 26
Type Ii Diabetes Mellitus 12 17
Type 2 Diabetes 26 64
Diabetes Mellitus, Non-Insulin-Dependent, Susceptibility to 58
Diabetes Mellitus, Noninsulin-Dependent, Susceptibility to 58
Diabetes Mellitus, Noninsulin-Dependent, Late Onset 58
Diabetes Mellitus, Noninsulin-Dependent, Late-Onset 6
Diabetes Mellitus, Type Ii, Susceptibility to 58
Diabetes Mellitus, Noninsulin-Dependent, 2 58
Hypertension, Insulin Resistance-Related 58
Non-Insulin-Dependent Diabetes Mellitus 12
Diabetes, Type Ii, Susceptibility to 6
Diabetes, Type 2, Susceptibility to 58
Maturity-Onset Diabetes Mellitus 26
Diabetes Mellitus, Type Ii; T2d 58
Diabetes Mellitus, Adult-Onset 26
Diabetes Mellitus Type Ii 76
Adult-Onset Diabetes 26
Diabetes Mellitus 74
Diabetes, Type 2 58
Type Ii Diabetes 15
Diabetes Type 2 44
Aodm 26

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
diabetes mellitus, noninsulin-dependent:
Onset and clinical course late onset
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:9352
OMIM 58 125853
KEGG 38 H00409
MeSH 45 D003924
NCIt 51 C26747
SNOMED-CT 69 44054006
SNOMED-CT via HPO 70 263681008 48606007

Summaries for Diabetes Mellitus, Noninsulin-Dependent

MedlinePlus : 44 Diabetes means your blood glucose, or blood sugar, levels are too high. With type 2 diabetes, the more common type, your body does not make or use insulin well. Insulin is a hormone that helps glucose get into your cells to give them energy. Without insulin, too much glucose stays in your blood. Over time, high blood glucose can lead to serious problems with your heart, eyes, kidneys, nerves, and gums and teeth. You have a higher risk of type 2 diabetes if you are older, have obesity, have a family history of diabetes, or do not exercise. Having prediabetes also increases your risk. Prediabetes means that your blood sugar is higher than normal but not high enough to be called diabetes. If you are at risk for type 2 diabetes, you may be able to delay or prevent developing it by making some lifestyle changes. The symptoms of type 2 diabetes appear slowly. Some people do not notice symptoms at all. The symptoms can include Being very thirsty Urinating often Feeling very hungry or tired Losing weight without trying Having sores that heal slowly Having blurry eyesight Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Many people can manage their diabetes through healthy eating, physical activity, and blood glucose testing. Some people also need to take diabetes medicines. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, Noninsulin-Dependent, also known as insulin resistance, is related to maturity-onset diabetes of the young, type 1 and maturity-onset diabetes of the young, type 13, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Diabetes Mellitus, Noninsulin-Dependent is IRS1 (Insulin Receptor Substrate 1), and among its related pathways/superpathways are Cell cycle and p53 signaling pathway. The drugs Metformin and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include Pancreas and Adipose, and related phenotypes are type ii diabetes mellitus and insulin resistance

Disease Ontology : 12 A diabetes mellitus that involves high blood glucose resulting from cells fail to use insulin properly.

Genetics Home Reference : 26 Type 2 diabetes is a disorder characterized by abnormally high blood sugar levels. In this form of diabetes, the body stops using and making insulin properly. Insulin is a hormone produced in the pancreas that helps regulate blood sugar levels. Specifically, insulin controls how much glucose (a type of sugar) is passed from the blood into cells, where it is used as an energy source. When blood sugar levels are high (such as after a meal), the pancreas releases insulin to move the excess glucose into cells, which reduces the amount of glucose in the blood.

UniProtKB/Swiss-Prot : 76 Diabetes mellitus, non-insulin-dependent: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

PubMed Health : 64 About type 2 diabetes: Type 2 diabetes (diabetes mellitus) is a metabolic disease that causes sugar to build up in the blood stream. The severity of diabetes can vary quite a bit: Some people only have to make minor changes to their lifestyle after they are diagnosed. Just losing a little weight and getting a bit more exercise may be enough for them to manage their diabetes. Other people who have type 2 diabetes need long-term treatment that involves taking tablets or insulin. It is then especially important for them to have a good understanding of their disease and know what they can do to stay healthy.There are two main types of diabetes. Type 1 diabetes usually develops in childhood or teenage years. This disease is a result of damage to the pancreas that leaves it producing either very little insulin or none at all.Things are different in type 2 diabetes, where insulin is made by the pancreas but the body’s cells gradually lose the ability to absorb and use the insulin. In the past, type 2 diabetes was often referred to as “adult-onset” diabetes because it is commonly diagnosed later in life. Type 2 diabetes is much more common than type 1 diabetes. About 90% of people who have diabetes have type 2 diabetes.

Wikipedia : 77 Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term metabolic disorder that is... more...

Description from OMIM: 125853

Related Diseases for Diabetes Mellitus, Noninsulin-Dependent

Diseases in the Diabetes Mellitus, Noninsulin-Dependent family:

Diabetes Mellitus, Noninsulin-Dependent, 1 Diabetes Mellitus, Noninsulin-Dependent, 2
Diabetes Mellitus, Noninsulin-Dependent, 3 Diabetes Mellitus, Noninsulin-Dependent, 4
Diabetes Mellitus, Noninsulin-Dependent, 5

Diseases related to Diabetes Mellitus, Noninsulin-Dependent via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 944)
# Related Disease Score Top Affiliating Genes
1 maturity-onset diabetes of the young, type 1 36.6 INSR HNF4A HNF1B GPD2 GCK GCGR
2 maturity-onset diabetes of the young, type 13 35.7 ABCC8 GCK HNF4A KCNJ11 NEUROD1 PAX4
3 maturity-onset diabetes of the young, type 6 35.4 GCK HNF1B HNF4A NEUROD1
4 maturity-onset diabetes of the young, type 7 35.4 GCK HNF1B HNF4A NEUROD1
5 renal cysts and diabetes syndrome 34.9 GCK HNF1B HNF4A NEUROD1
6 maturity-onset diabetes of the young, type 14 34.8 ABCC8 GCK
7 monogenic diabetes 33.3 ABCC8 GCK HNF4A KCNJ11 PAX4
8 maturity-onset diabetes of the young, type 2 33.0 GCK HNF1B HNF4A
9 diabetes mellitus, permanent neonatal 32.9 ABCC8 GCK KCNJ11
10 diabetes mellitus 32.8 WFS1 SLC30A8 SLC2A2 RETN PPP1R3A PPARG
11 glucose intolerance 32.1 GCK INSR IRS1 PPARG RETN
12 hyperglycemia 31.8 ABCC8 GCGR GCK INSR IRS1 KCNJ11
13 hyperinsulinism 31.6 ABCC8 GCK HNF4A INSR KCNJ11
14 maturity-onset diabetes of the young 31.6 ABCC8 GCK HNF1B HNF4A IRS1 KCNJ11
15 hyperinsulinemic hypoglycemia 31.5 ABCC8 GCK HNF4A INSR KCNJ11
16 gestational diabetes 31.3 GCK HNF4A INSR IRS1 KCNJ11 RETN
17 glucose metabolism disease 31.2 ABCC8 GCK IRS1 KCNJ11 PPARG RETN
18 body mass index quantitative trait locus 11 31.2 ENPP1 GCK INSR IRS1 PPARG RETN
19 overnutrition 31.2 IRS1 PPARG RETN
20 maturity-onset diabetes of the young, type 3 31.1 GCK HNF1B HNF4A NEUROD1
21 hypoglycemia 31.0 ABCC8 AKT2 GCK INSR KCNJ11
22 neonatal diabetes mellitus 30.9 ABCC8 GCK HNF1B KCNJ11 NEUROD1 SLC2A2
23 insulinoma 30.8 ABCC8 GCK SLC2A2 WFS1
24 maturity-onset diabetes of the young, type 4 30.8 GCK HNF1B HNF4A
25 pancreatic agenesis 30.7 ABCC8 GCK KCNJ11
26 insulin-like growth factor i 30.6 AKT2 INSR IRS1
27 maturity-onset diabetes of the young, type 8, with exocrine dysfunction 12.9
28 maturity-onset diabetes of the young, type 9 12.9
29 maturity-onset diabetes of the young, type 10 12.9
30 insulin-resistant acanthosis nigricans, type a 12.8
31 maturity-onset diabetes of the young, type 11 12.8
32 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 12.7
33 fanconi renotubular syndrome 4 with maturity-onset diabetes of the young 12.7
34 diabetes mellitus, noninsulin-dependent, 1 12.7
35 diabetes mellitus, noninsulin-dependent, 5 12.7
36 diabetes mellitus, noninsulin-dependent, 2 12.7
37 diabetes mellitus, noninsulin-dependent, 4 12.6
38 diabetes mellitus, noninsulin-dependent, 3 12.6
39 diabetes mellitus, insulin-resistant, with acanthosis nigricans 12.6
40 insulin-resistance type b 12.6
41 intrauterine growth restriction-short stature-early adult-onset diabetes syndrome 12.3
42 pseudoacromegaly with severe insulin resistance 12.2
43 insr-related severe syndromic insulin resistance 12.2
44 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 12.2
45 microcephalic primordial dwarfism-insulin resistance syndrome 12.2
46 short fifth metacarpals-insulin resistance syndrome 12.2
47 hair-an syndrome 12.1
48 short syndrome 12.0
49 bangstad syndrome 11.8
50 donohue syndrome 11.8

Comorbidity relations with Diabetes Mellitus, Noninsulin-Dependent via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Ischemic Heart Disease Peripheral Vascular Disease
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Diabetes Mellitus, Noninsulin-Dependent:



Diseases related to Diabetes Mellitus, Noninsulin-Dependent

Symptoms & Phenotypes for Diabetes Mellitus, Noninsulin-Dependent

Human phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

33
# Description HPO Frequency HPO Source Accession
1 type ii diabetes mellitus 33 HP:0005978
2 insulin resistance 33 HP:0000855
3 decreased waist to hip ratio 33 HP:0031820

Symptoms via clinical synopsis from OMIM:

58
Lab:
insulin resistance
decreased glucose disposal

Endo:
noninsulin-dependent diabetes mellitus

Misc:
late onset

Clinical features from OMIM:

125853

UMLS symptoms related to Diabetes Mellitus, Noninsulin-Dependent:


tremor, angina pectoris, equilibration disorder, symptoms

GenomeRNAi Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent according to GeneCards Suite gene sharing:

27 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.74 MAPK8IP1
2 Decreased viability GR00221-A-1 10.74 AKT2 GCK INSR PPARG IRS1
3 Decreased viability GR00221-A-2 10.74 GCK INSR PPARG IRS1
4 Decreased viability GR00221-A-3 10.74 AKT2 GCK INSR PPARG
5 Decreased viability GR00221-A-4 10.74 AKT2 GCK INSR PPARG MAPK8IP1
6 Decreased viability GR00231-A 10.74 GCK
7 Decreased viability GR00301-A 10.74 AKT2 MAPK8IP1
8 Decreased viability GR00342-S-2 10.74 IRS1
9 Decreased viability GR00342-S-3 10.74 AKT2 IRS1 MAPK8IP1
10 Decreased viability GR00402-S-2 10.74 AKT2 GCK INSR PPARG IRS1 MAPK8IP1
11 no effect GR00402-S-1 9.92 ABCC8 AKT2 ENPP1 GCGR GCK GPD2
12 Decreased viability in esophageal squamous lineage GR00235-A 9.7 ABCC8 GCGR HNF1B HNF4A INSR MAPK8IP1

MGI Mouse Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.28 AKT2 ENPP1 GCGR GCK GPD2 HNF1B
2 endocrine/exocrine gland MP:0005379 10.27 ABCC8 AKT2 GCGR GCK GPD2 HNF1B
3 homeostasis/metabolism MP:0005376 10.26 ABCC8 AKT2 ENPP1 GCGR GCK GPD2
4 adipose tissue MP:0005375 10.16 AKT2 ENPP1 GCGR GPD2 INSR IRS1
5 cellular MP:0005384 10.14 AKT2 ENPP1 GCGR HNF4A INSR IRS1
6 behavior/neurological MP:0005386 10.13 ENPP1 GCGR GPD2 INSR KCNJ11 MAPK8IP1
7 liver/biliary system MP:0005370 10 AKT2 ENPP1 GCGR GCK GPD2 HNF1B
8 mortality/aging MP:0010768 9.86 AKT2 ENPP1 GCGR GCK GPD2 HNF1B
9 muscle MP:0005369 9.28 AKT2 ENPP1 HNF1B INSR IRS1 KCNJ11

Drugs & Therapeutics for Diabetes Mellitus, Noninsulin-Dependent

PubMedHealth treatment related to Diabetes Mellitus, Noninsulin-Dependent: 64

A number of factors influence which treatment approach for type 2 diabetes is most suitable: They include age, general physical condition, other health problems, life circumstances and personal goals.Sometimes just changing your lifestyle can have a positive effect: Losing weight and getting more exercise can make insulin more effective and lower blood sugar levels. Quitting smoking helps to reduce the risk of cardiovascular disease. Making these kinds of changes is sometimes enough to manage the condition and associated risks.If very overweight (obese) people find it hard to lose weight, surgical approaches such as stomach stapling may be an option.Some people depend on medication to regulate their blood sugar levels. The medication options include taking tablets, injecting insulin or medication called incretin mimetics (hormone-like substances that are designed to increase the body's insulin production). It's also possible to combine tablets and injections. The most common medications used to treat type 2 diabetes (antidiabetic drugs) are metformin and sulfonylureas. Newer antidiabetic drugs are also available – but there are still many unanswered questions about their effects.Depending on what other symptoms and illnesses a person has, different kinds of medication can be used to lower particular risks. For example, many people who have type 2 diabetes also have high blood pressure.The main medications that can lower the risk of cardiovascular diseaselower blood pressure (antihypertensives),prevent blood clotting (ASA, the drug in medications like Aspirin), orreduce cholesterol levels (statins).

Drugs for Diabetes Mellitus, Noninsulin-Dependent (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1265)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
2
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 668270-12-0 10096344
3
Mineral oil Approved, Vet_approved Phase 4,Phase 3,Not Applicable 8042-47-5
4
Insulin glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
5
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051
6
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 111025-46-8 4829
7
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
8
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 361442-04-8 11243969
9
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29094-61-9 3478
10
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 56180-94-0 441184
11
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 207748-29-6
12
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 116094-23-6 16132418
13
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
14
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 204656-20-2 44147092
15
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133107-64-9
16
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93479-97-1 3476
17
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169148-63-4 5311023
18
Clopidogrel Approved Phase 4,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
19
Ramipril Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 87333-19-5 5362129
20
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 128-13-2 31401
21
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
22
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
23
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 137862-53-4 60846
24
Glucagon Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 16941-32-5
25
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 850649-61-5 11450633
26
Canagliflozin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 842133-18-0
27
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274901-16-5 6918537
28
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
29
Gliclazide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21187-98-4 3475
30
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 54-31-9 3440
31
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 138402-11-6 3749
32
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-93-5 3639
33
Atenolol Approved Phase 4,Not Applicable 29122-68-7 2249
34
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
35
Clonidine Approved Phase 4,Phase 3 4205-90-7 2803
36
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
37
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88150-42-9 2162
38
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Not Applicable 49562-28-9 3339
39
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Not Applicable 76420-72-9 6917719
40
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 75847-73-3 5362032 40466924
41
AT-101 Approved, Investigational Phase 4,Not Applicable 90141-22-3, 652-67-5 12597
42
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 10102-43-9 145068
43
Isosorbide Dinitrate Approved, Investigational Phase 4,Not Applicable 87-33-2 6883
44
Ticagrelor Approved Phase 4,Phase 3,Not Applicable 274693-27-5 9871419
45
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 135062-02-1 65981
46
Glyburide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 10238-21-8 3488
47
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0
48
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0, 481-30-1 6013 10204
49
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
50
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416

Interventional clinical trials:

(show top 50) (show all 10693)
# Name Status NCT ID Phase Drugs
1 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
2 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
3 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
4 The Assessment of the Effect of Vitamin D Supplementation on Inflammatory and Endothelial Factors in the Patients With Type 2 Diabetes . Unknown status NCT03008057 Phase 4
5 The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Unknown status NCT02261545 Phase 4
6 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
7 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
8 Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
9 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4 Exenatide
10 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
11 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
12 Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy Unknown status NCT03112538 Phase 4 Multiple daily injections of insulin
13 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
14 Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes Unknown status NCT02344186 Phase 4 Liraglutide
15 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
16 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices Unknown status NCT02361489 Phase 4
17 Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes Unknown status NCT02605772 Phase 4 Acarbose;Metformin;Saxagliptin
18 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4 dapagliflozin;glimpiride
19 Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes Unknown status NCT00747409 Phase 4 insulin aspart and detemir (NovoRapid, Levemir);human regular insulin and NPH insulin (Actrapid, Protaphne)
20 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
21 Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes Unknown status NCT02674893 Phase 4 Liraglutide
22 Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus Unknown status NCT02775253 Phase 4
23 Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy Unknown status NCT02129985 Phase 4 Exenatide;Metformin
24 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
25 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
26 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4 Euthyrox (levothyroxine)
27 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
28 The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics Unknown status NCT01478776 Phase 4
29 A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes Unknown status NCT02606617 Phase 4 Mosapride;Placebo
30 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
31 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
32 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
33 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
34 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
35 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
36 Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
37 Vascular Effects of Sitagliptin in Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
38 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
39 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
40 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
41 Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes Unknown status NCT01978405 Phase 4 Alpha lipoic acid
42 Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients Unknown status NCT01768208 Phase 4 Saxagliptin
43 the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin Unknown status NCT02438397 Phase 4 premix insulin;metformin;Acarbose
44 Glycemic Durability After Metformin Failure Unknown status NCT02142309 Phase 4 Glimepiride;Vildagliptin;Pioglitazone;Canagliflozin
45 Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
46 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
47 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
48 Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells Unknown status NCT00523393 Phase 4 Insulin Glargin;Human Insulin
49 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
50 Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes Unknown status NCT02526810 Phase 4 insulin lispro;Insulin Glargine

Search NIH Clinical Center for Diabetes Mellitus, Noninsulin-Dependent

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetes mellitus, type 2

Genetic Tests for Diabetes Mellitus, Noninsulin-Dependent

Genetic tests related to Diabetes Mellitus, Noninsulin-Dependent:

# Genetic test Affiliating Genes
1 Diabetes Mellitus Type 2 30 ABCC8 AKT2 ENPP1 GCGR GCK GPD2 HMGA1 HNF1A HNF1B HNF4A IGF2BP2 IRS1 IRS2 KCNJ11 LIPC MAPK8IP1 MTNR1B NEUROD1 PAX4 PDX1 PPARG PPP1R3A PTPN1 RETN SLC2A2 SLC30A8 TCF7L2 WFS1
2 Insulin Resistance 30

Anatomical Context for Diabetes Mellitus, Noninsulin-Dependent

MalaCards organs/tissues related to Diabetes Mellitus, Noninsulin-Dependent:

42
Liver, Ovary, Heart, Endothelial, Kidney, Skeletal Muscle, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Diabetes Mellitus, Noninsulin-Dependent:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Affected by disease, potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Diabetes Mellitus, Noninsulin-Dependent

Articles related to Diabetes Mellitus, Noninsulin-Dependent:

(show top 50) (show all 9524)
# Title Authors Year
1
Bone Marrow Mesenchymal Stem Cells-Derived Exosomal MiR-29b-3p Regulates Aging-Associated Insulin Resistance. ( 30715852 )
2019
2
Broadening the definition of brain insulin resistance in aging and Alzheimer's disease. ( 30576640 )
2019
3
Peroxiredoxin2 Deficiency Aggravates Aging-Induced Insulin Resistance and Declines Muscle Strength. ( 29733327 )
2019
4
The Association of Metabolic Syndrome and Insulin Resistance in Early-Onset Androgenetic Alopecia in Males: A Case-Control Study. ( 30745631 )
2019
5
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study. ( 30762811 )
2019
6
Insulin resistance vary across connective tissue diseases patients: comparison between rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. ( 30652676 )
2019
7
Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment. ( 30704150 )
2019
8
Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells. ( 30759303 )
2019
9
Correlations of insulin resistance and HbA1c with cytokines IGF-1, bFGF and IL-6 in the aqueous humor of patients with diabetic cataract. ( 30657541 )
2019
10
The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity. ( 30711385 )
2019
11
Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes. ( 30837902 )
2019
12
Insulin resistance and obesity, and their association with depression in relatively young people: findings from a large UK birth cohort. ( 30854996 )
2019
13
Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. ( 30695707 )
2019
14
Associations between Fatty Acid-Binding Protein 4⁻A Proinflammatory Adipokine and Insulin Resistance, Gestational and Type 2 Diabetes Mellitus. ( 30857223 )
2019
15
Serum CCN3 levels are increased in type 2 diabetes mellitus and associated with obesity, insulin resistance and inflammation. ( 30876855 )
2019
16
Letter: Association of Thigh Muscle Mass with Insulin Resistance and Incident Type 2 Diabetes Mellitus in Japanese Americans (Diabetes Metab J 2018;42:488-95). ( 30793553 )
2019
17
Response: Association of Thigh Muscle Mass with Insulin Resistance and Incident Type 2 Diabetes Mellitus in Japanese Americans (Diabetes Metab J 2018;42:488-95). ( 30793554 )
2019
18
Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with Type 2 diabetes mellitus. ( 30716347 )
2019
19
New-onset post-transplant diabetes mellitus after allogeneic hematopoietic cell transplant is initiated by insulin resistance, not immunosuppressive medications. ( 30738170 )
2019
20
Methylation of HIF3A promoter CpG islands contributes to insulin resistance in gestational diabetes mellitus. ( 30743315 )
2019
21
The Profile of Plasma Free Amino Acids in Type 2 Diabetes Mellitus with Insulin Resistance: Association with Microalbuminuria and Macroalbuminuria. ( 30706418 )
2019
22
Accumulation of advanced glycation end products in the skin is accelerated in relation to insulin resistance in people with Type 1 diabetes mellitus. ( 30706538 )
2019
23
Correlation between basal metabolic rate, visceral fat and insulin resistance among type 2 diabetes mellitus with peripheral neuropathy. ( 30641723 )
2019
24
B Lymphocytes Are Predictors of Insulin Resistance in Women with Gestational Diabetes Mellitus. ( 30621567 )
2019
25
Lipoprotein insulin resistance index, a high-throughput measure of insulin resistance, is associated with incident type II diabetes mellitus in the Prevention of Renal and Vascular End-Stage Disease study. ( 30591414 )
2019
26
Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis. ( 30506494 )
2019
27
Bile acid metabolism is altered in those with insulin resistance after gestational diabetes mellitus. ( 30508519 )
2019
28
Association of the muscle/fat mass ratio with insulin resistance in gestational diabetes mellitus. ( 30393250 )
2019
29
miR-335-5p induces insulin resistance and pancreatic islet β-cell secretion in gestational diabetes mellitus mice through VASH1-mediated TGF-β signaling pathway. ( 30341900 )
2019
30
Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: A pilot exploratory study. ( 29862667 )
2019
31
Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: A double-blind randomized controlled trial. ( 29781243 )
2019
32
Correction to: Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. ( 30694351 )
2019
33
Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell? ( 30893108 )
2019
34
Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. ( 30773673 )
2019
35
Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial. ( 30796508 )
2019
36
Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet. ( 30611282 )
2019
37
Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes. ( 30625285 )
2019
38
Insulin Resistance: A Hidden Risk Factor for Gastric Cancer? ( 30893982 )
2019
39
Interactions among insulin resistance, inflammation factors, obesity-related gene polymorphisms, environmental risk factors, and diet in the development of gestational diabetes mellitus. ( 29519182 )
2019
40
Glucose intolerance in monosodium glutamate obesity is linked to hyperglucagonemia and insulin resistance in α cells. ( 30317580 )
2019
41
Association Between Serum Adipsin Levels and Insulin Resistance in Subjects With Various Degrees of Glucose Intolerance. ( 30746502 )
2019
42
Effects of liver function, insulin resistance and inflammatory factors on vascular endothelial dilation function and prognosis of coronary heart disease patients complicated with NAFLD. ( 30680007 )
2019
43
Circulating microRNA-155 is associated with insulin resistance in chronic hepatitis C patients. ( 30852102 )
2019
44
Previous hepatitis E virus infection, cirrhosis and insulin resistance in patients with chronic hepatitis C. ( 30836071 )
2019
45
Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. ( 30024489 )
2019
46
Hyperandrogenism and insulin resistance induce gravid uterine defects in association with mitochondrial dysfunction and aberrant ROS production. ( 30860876 )
2019
47
Cardiac fibroblast activation and hyaluronan synthesis in response to hyperglycemia and diet-induced insulin resistance. ( 30755628 )
2019
48
Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose Tolerant Subjects. ( 30789980 )
2019
49
Insulin resistance and diabetes in hyperthyroidism: a possible role for oxygen and nitrogen reactive species. ( 30843740 )
2019
50
Fu Brick Tea Alleviates Chronic Kidney Disease of Rats with High Fat Diet Consumption through Attenuating Insulin Resistance in Skeletal Muscle. ( 30829482 )
2019